Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
Titel:
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
Auteur:
Iveson, Timothy Donehower, Ross C Davidenko, Irina Tjulandin, Sergey Deptala, Andrzej Harrison, Mark Nirni, Somanath Lakshmaiah, Kuntegowdanahalli Thomas, Anne Jiang, Yizhou Zhu, Min Tang, Rui Anderson, Abraham Dubey, Sarita Oliner, Kelly S Loh, Elwyn